Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer

Launched by FIRST AFFILIATED HOSPITAL XI'AN JIAOTONG UNIVERSITY · Aug 28, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how the environment around prostate cancer tumors changes during different treatment stages. Researchers want to understand how certain immune cells and proteins behave in prostate cancer, especially after patients receive neoadjuvant therapy (treatment given before surgery) or when they have advanced prostate cancer that no longer responds to hormone therapy (known as CRPC). By comparing tumor samples taken at various stages, the study aims to answer important questions about the immune system's effectiveness in fighting cancer.

To participate in this trial, men diagnosed with prostate cancer who have received neoadjuvant therapy or have been diagnosed with CRPC may be eligible. However, those with certain viral infections, like HIV, or who do not have suitable biopsy samples will not be able to join. Participants will provide tumor samples, and researchers will analyze these to gather insights that could help improve future treatments. The trial is not yet open for recruitment, so interested individuals should keep an eye out for updates.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • The patient was diagnosed with prostate cancer.
• • The patient underwent neoadjuvant therapy or was diagnosed with CRPC.
• Exclusion Criteria:
• • When it is detected that the patient has a viral infection that interferes with the human genome, such as HIV infection, etc.
• • Biopsy and/or surgically removed prostate cancer tissue was not eligible for the study.